Structure and Function of Snake Venom Proteins Affecting Platelet Plug Formation

Taei Matsui 1*, Jiharu Hamako 2 and Koiti Titani 3

1 Department of Biology, Faculty of Medical Technology, Fujita Health University School of Health Sciences, Toyoake, Aichi 470-1192, Japan
2 Department of Physiology, Faculty of Medical Information Technology, Fujita Health University School of Health Sciences, Toyoake, Aichi 470-1192, Japan; E-Mail: jhamako@fujita-hu.ac.jp
3 Division of Medical Polymer Sciences, Institute for Comprehensive Medical Sciences, Fujita Health University, Toyoake, Aichi 470-1192, Japan; E-Mail: ktitani@crest.ocn.ne.jp

* Author to whom correspondence should be addressed; E-Mail: tmatsui@fujita-hu.ac.jp; Tel.: +81-562-93-2594; Fax: +81-562-93-4595.

Received: 1 December 2009; in revised form: 18 December 2009 / Accepted: 24 December 2009 / Published: 28 December 2009

Abstract: Many snake venom proteins have been isolated that affect platelet plug formation by interacting either with platelet integrins, membrane glycoprotein Ib (GPIb), or plasma von Willebrand factor (VWF). Among them, disintegrins purified from various snake venoms are strong inhibitors of platelet aggregation. Botrocetin and bitiscetin derived from Bothrops jararaca and Bitis arietans venom, respectively, induce VWF-dependent platelet agglutination in vitro. Several GPIb-binding proteins have also been isolated from snake venoms. In this review, we focus on the structure and function of those snake venom proteins that influence platelet plug formation. These proteins are potentially useful as reagents for the sub-diagnosis of platelet disorder or von Willebrand disease, as well as for clinical and basic research of thrombosis and hemostasis.

Keywords: disintegrin; snake venom; von Willebrand factor; platelet GPIb; thrombosis
1. Introduction

Platelet plug formation is an important step in hemostasis preceding the initiation of the coagulation cascade. Plasma von Willebrand factor (VWF) and its platelet membrane receptors, glycoproteins (GP) Ib and IIb/IIIa, are a prerequisite for this first event [1,2]. When subendothelial matrices such as collagens are exposed at the site of vascular damage, VWF immediately sticks to them leading to the conformational change under high shear stress and platelets start rolling on the immobilized VWF via its surface GPIb molecules. The continuous interaction between VWF and GPIb potentiates platelet inside-out signal transduction, leading to the conformational change of cryptic GPIIb/IIIa molecules. GPIIb/IIIa is an integrin alpha IIb, beta 3 that recognizes the Arg-Gly-Asp (RGD) sequence in fibrinogen or VWF, and these interactions induce platelet-platelet aggregation to form a primary platelet plug. The coagulation sequence is initiated on the surface of activated platelets and the resulting fibrin clot strengthens the platelet plug by trapping red blood cells into the sticky mesh-like structure.

Snake venoms contain a variety of bioactive substances that influence hemostasis, thrombosis, and coagulation of mammalian blood [3–6]. In this short review, we focus on snake venom proteins that affect platelet plug formation. These proteins have been used not only as specific reagents for the basic study of thrombosis and hemostasis, but are also expected to have clinical applications, e.g., as anti-thrombotic or diagnostic reagents [7–9].

2. Structure and Function of Disintegrins

The first disintegrin (trigamin) was discovered and purified from the venom of Trimeresurus gramineus by Huang et al. in 1987 [10] as a strong platelet aggregation inhibitor [11]. During the last two decades, more than 78 disintegrins have been reported from snake venoms. Recently, a standardized scientific classification and nomenclature for disintegrins has been proposed [12]. Disintegrins are relatively Cys-rich small polypeptides (Mr: 5~15 kDa) that potently block the binding of fibrinogen and VWF to GPIIb/IIIa complexes in ADP- or thrombin-activated platelets [13]. The inhibitory effect of disintegrin is due to its typical RGD sequence motif that competitively interacts with integrin receptors. Since disintegrin elicits a more than 1,000-fold higher inhibitory effect on platelet aggregation compared to the linear tetrapeptide Arg-Gly-Asp-Ser, a specific conformation, stabilized for example by disulfide bridges or other synergic domains, should be responsible for its higher activity.

The three-dimensional (3D) structures of several disintegrins such as acostatin [14], kistrin [15], echistatin [16], trilflavin (trimestatin) [17], salmosin [18], schistatin [19], disintegrin from Echis carinatus [20] and rhodostomin have been elucidated by NMR or X-ray crystallographic studies (Figure 1). An NMR study of linear and disulfide-looped peptides containing RGD residues has indicated that the stability of the cyclic form derives from the packing of the Arg and Asp side chains [22]. Based on the crystal structure of trilflavin (trimestatin) from Trimeresurus flavoviridis venom, a number of turns and loops form a rigid core stabilized by six disulfide bonds. The RGD sequence is located at the tip of a hairpin loop in such a manner that the Arg and Asp side chains point in opposite directions (Figure 1). Fujii et al. [17] suggested that the Arg and Asp bind to the propeller domain and beta-A domain of integrin, respectively, and that the C-terminal region of Arg-Trp-Asn is...
another potential binding site with integrin receptors. Bilgrami et al. reported the homodimer [19] and heterodimer [20] 3D structures of the disintegrin schistatin from *E. carinatus* venom.

**Figure 1.** Structures of disintegrins. The 3D structures of triflavin (PDB ID; 1J2L), monomeric form of schistatin (1RMR), disintegrin from *E. carinatus* (1TEJ) and acostatin (3C05) were generated with RasMol [21]. The RGD sequence and Cys residues were shown in spacefill and sticks, respectively.

There is interest in applying disintegrin motifs for therapeutic purposes to prevent thrombus formation; however, the RGD motif effectively inhibits adhesive functions of other RGD-dependent integrins. There was a possibility that the RGD-containing peptide might have an adverse affect on cellular functions when administered. Since the RGD motif is not specific to GPIIb/IIIa, the specific motif for GPIIb/IIIa has been explored. Scarborough et al. [23] screened 62 snake venoms and found that the disintegrin, barbourin, has sole specificity to GPIIb/IIIa. Interestingly, barbourin contains a Lys-Gly-Asp (KGD) sequence within a disulfide ring instead of an RGD sequence. The KGD motif of barbourin was selected and designed as a therapeutic peptide named “eptifibatide” [24,25]. Eptifibatide elicited significant clinical benefits as an adjunctive therapy in patients undergoing selective percutaneous coronary intervention with stent implantation in the ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrin Therapy) study, in patients with acute coronary syndromes in the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrin Therapy) trial, and in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) trial [26–28]. Other than eptifibatide, a recombinant barbourin-albumin fusion protein also shows an antithrombotic effect *in vivo* in animal experiments [29].

Snake venoms also contain metalloproteinases with a disintegrin domain termed ADAM [30], and ADAM family proteins have been found to take part in a variety of cellular response [31] such as sperm-egg binding (fertilin) [32], muscle fusion [33], or intracellular cleavage and activation of Notch [34]. Kaouthiagin purified from *Naja naja kaouthia* venom is an ADAM protein containing two disintegrin-like sequences [35]. Although the exact function of the disintegrin-like domain is unknown, kaouthiagin cleaves a single site of VWF resulting in the disruption of the platelet agglutination-inducing activity of VWF [36].
3. Structure and Function of VWF-Modulating Snake Venom Proteins

The platelet agglutination mediated by the VWF-GP Ib axis never occurs under static conditions, but is inducible with the assistance of cofactors in vitro even under static conditions. The antibiotic ristocetin has been used as a cofactor for VWF in clinical settings to sub-diagnose von Willebrand disease or platelet disorders such as Bernard-Soulier syndrome. However, ristocetin has some limitations, such as the fact that it shows no effect on dog platelets and its working concentration is between 0.5~1.5 mg/mL; at more than 2.0 mg/mL, it precipitates fibrinogen by flocculation [37,38]. To overcome these defects, Read et al. screened 73 snake venoms to find a novel cofactor for VWF [39]. They found snake venoms from five species (Bothrops alternatus, B. jararaca, B. medusa, B. neuwiedii, and Bitis arietans) that have such cofactor activity (coagglutinin) for VWF. Two VWF-modulating venom cofactors, botrocetin and bitiscetin, have been purified and extensively studied.

Botrocetin from B. jararaca and bitiscetin from B. arietans clearly agglutinate fixed or fresh platelets in the presence of VWF irrespective of mammalian species [40]. The effective concentration for inducing VWF-dependent platelet agglutination is approximately 2 to 5 μg/mL. These cofactors are disulfide-linked heterodimers (approximately 25–27 kDa) comprised of similar α and β- subunits, each of which contains a C-type lectin-like motif, although they show neither sugar-binding nor Ca2+-dependent activity [41,42]. Botrocetin α- and β-subunits show a high degree of similarity to the GPIb-binding proteins from the same species, B. jararaca (64% and 56% for α- and β- subunits, respectively [43]), but relatively low similarity to bitiscetin (41% and 44% for α- and β- subunits, respectively) even though botrocetin has the same function as bitiscetin. Since botrocetin has a highly acidic pI (4.6), contrary to bitiscetin (9.1), they might bind to a different site on VWF; however, Ala-scanning analysis of targeted residues in the A1 domain together with crystal structural analysis clearly indicate that both proteins bind to the VWF A1 domain in very close proximity [44–49]. Obert et al. [50] found a second cofactor from B. arietans venom, bitiscetin-2, which also induces a VWF-GP Ib interaction. Bitiscetin-2 binds to the A3 domain of VWF, a collagen-type III binding site, but not to the A1 domain. The partial N-terminal amino acid sequence of bitiscetin-2 is similar to but distinct from that of bitiscetin. They suggested that bitiscetin-2 induces a long-range conformational change of the A1 domain by acting at the A3 domain level in a way similar to that of collagen under high shear-stress conditions.

The 3D structures of botrocetin and bitiscetin were elucidated at 1.8 and 2.0 Å resolution, respectively, in 2001 (Figure 2) [45,46]. The overall 3D structures of botrocetin and bitiscetin expectedly resemble other C-type lectin-like snake venom proteins such as FIX/X-BP [51], FX-BP from Deinagkistrodon acutus [52], GP-Ib-binding protein (flavocetin A) from T. flavoviridis [53], and GPVI-binding protein (convulxin) from Crotalus durissusterrificus [54]. Both subunits are composed of two helices and five to eight strands, forming a globular domain with an extended loop domain (Figure 2). Each loop domain of the subunit extends to a globular domain on the opposite subunit, and they embrace each other by hydrophobic interactions in addition to an inter-subunit disulfide bridge. This bow tie-like structure provides a central concave area hinged by both subunits, serving as a ligand binding site.
Botrocetin binds to VWF A1 domain via its concave region with comparable contributions from the α- (43%) and β- (57%) subunits. The botrocetin and bitiscetin binding sites on VWF overlap at the A1 domain, but the direction of the long-axis of bitiscetin is almost perpendicular to that of botrocetin (Figure 3). It seems likely that the β-subunit of botrocetin and the α-subunit of bitiscetin have a crucial role in interaction with GPIb. The $K_d$ values for botrocetin and bitiscetin binding to the VWF A1 domain are estimated to be 12nM [56] and 2 nM [48], respectively.

Botrocetin and bitiscetin appear to modulate VWF susceptible to GPIb by invoking an allosteric structural change on the GPIb-binding domain of VWF. However, contrary to expectation, crystal structures of the A1 domain complexed with botrocetin and bitiscetin have indicated no significant conformational changes in the GPIb binding site of the A1 domain before or after binding with botrocetin or bitiscetin [48,57]. The importance of the anionic region of the GPIb domain for botrocetin-induced VWF binding suggests that it plays an essential role in the high affinity binding of GPIb to the botrocetin-A1 complex even though botrocetin does not bind to GPIb by itself. Several important residues on GPIb for botrocetin-induced platelet agglutination have been described [58]. Bitiscetin- or botrocetin-induced binding of GPIb to VWF may depend on electrostatic interactions between the anionic region of GPIb (sulfated Tyr residues) and a complementary electropositive spot contributed by the venom protein in the VWF A1-bitiscetin or VWF-botrocetin complex. It is conceivable that bitiscetin or botrocetin complexed with the A1 domain provide a supplemental platform suited for GPIb rather than inducing an allosteric conformational change on the A1 domain (Figure 3). This new hypothesis is in good agreement with results showing that GPIb without the sulfated Tyr residues fails to bind VWF in the presence of botrocetin [59]. Fukuda et al. [44] have recently found that botrocetin binds to and subsequently slides on the A1 surface to form a new interface with enhanced affinity to GPIb.
Figure 3. Complex structures of GPIbα-VWF A1- botrocetin and VWF A1-bitscetin. A: The 3D structures of botrocetin complexed with GPIbα (green) and VWF A1 domain (orange) [44]. Botrocetin and subunits were expressed as magenta (Bot,α) and blue (Bot,β), respectively. B: The 3D structures of bitscetin complexed with VWF A1 domain (orange) [48]. Bitscetin α and β subunits were expressed as magenta (Bit,α) and blue (Bit,β), respectively. Ribbon structures were drawn with Protein Workshop Viewer [55] using PDB file of 1U0N (A) and 1UEX (B).

4. Structure and Function of GPIb-binding Snake Venom Proteins

GPIb-binding proteins from snake venoms are categorized into two groups: GPIb-agonists and GPIb-antagonists. In addition to botrocetin, both groups have amino acid sequences highly similar to C-type lectin-like structures.

The first GPIb-agonist (alboaggregin-B) was purified from Trimeresurus albolabris venom by Peng et al. in 1991 [60]. Alboaggregins (A, B, and C), having highly similar primary sequences, bind to GPIb (and GPVI in the case of alboaggregin A) and induce platelet agglutination or aggregation [61]. They also inhibit VWF mediated platelet agglutination, suggesting that their binding sites overlap or are proximal to the VWF binding site on GPIb. This inhibitory effect strongly resembles GPIb-antagonists. The same activity has been found in mamushigin from Agkistrodon halys blomhoffii [62], bilinexin from A. bilineatus [63], agglucetin from A. acutus [64], agkicetin-C from D. acutus [65], mucetin (TMVA) from Chinese habu T. mucrosquamatus [66], and mucrocetin from Taiwan habu T. mucrosquamatus [67] venoms. Several GPIb-agonists induce only platelet agglutination in vitro, whilesome agonists further activate platelets leading to GPIIb/IIIa-dependent aggregation.

Alboaggregin A and agglucetin are tetrameric forms composed of disulfide-linked subunits [68]. Although the dimeric form is sufficient to induce platelet agglutination, the tetramer significantly enhances platelet aggregation and the release reaction. Agglucetin agglutinates formalin-fixed platelets in a GPIb-dependent manner, but also activates surface exposure of GPIIb/IIIa of intact platelets.
without significant elevation of intracellular Ca\textsuperscript{2+} mobilization and thromboxane B formation [64,68]. Mucetin also has several multimeric forms, including (αβ)\textsubscript{2} and (αβ)\textsubscript{4}, and activates platelets via GPIb. The platelet activation process by the mucetin-GPIb interaction is not clear, but Lu et al. [66] found that signaling by mucetin involves rapid Tyr phosphorylation of Syk, Src, LAT, and PLC\textsubscript{2}, with translocation of GPIb and the Fc receptor γ-chain to the cytoskeleton [69].

**Figure 4.** Structures of flavocetin and convulxin. The 3D structures of flavocetin-A (1C3A) and convulxin (1UMR) were drawn with Protein Workshop Viewer [55]. The α and β- subunits were expressed in magenta and blue, respectively. They forms cyclic tetramer (αβ)\textsubscript{4} composed of disulfide-linked four αβ-heterodimers.

The other GPIb-binding group, the GPIb-antagonists, also specifically binds to GPIb but do not induce platelet agglutination. They competitively block binding of VWF or alboaggregin to GPIb, resulting in the inhibition of platelet agglutination. Echicetin, a disulfide-linked heterodimer of two subunits, purified from *E. carinatus* was first described as a GPIb-antagonist by Peng et al. in 1993 [70]. GPIb-antagonists have been purified from the venom of many snake species, including flavocetin-A and -B from *T. flavoviridis* [71], tokaracetin from *T. tokarensis* [72], jararaca GPIb-BP (yoshitobin) from *B. jararaca* [73], dabocetin from *Daboia russellii siamensis* [74], and agkicetin from *D. acutus* [65].

The 3D structures of flavocetin-A [75], echicetin [76], and agkicetin [77] have been elucidated (Figures 2 and 4). Overall, they are similar to those of VWF-modulating proteins and GPIb-agonists, since they all belong to the C-type lectin-like protein family. Flavocetin-A is a high-molecular mass protein (149 kDa) with a unique 3D structure: a cyclic tetramer (αβ)\textsubscript{4} composed of four disulfide-linked αβ-heterodimers (Figure 4) [75]. The tetramerization is mediated by an interchain disulfide bridge between Cys residues at the C-terminus of the α-subunit and the N-terminus of the β-subunit in the neighboring αβ-heterodimer, in a manner of a “head-to-tail” interaction. This configuration is also found in the platelet activator convulxin, purified from *C.durissusterrificus* venom, which binds to GPVI (Figure 4) [54]. Although flavocetin-A shows an inhibitory effect on platelet agglutination, it induces small platelet aggregate formation by itself through partial activation of platelets due to its multivalent GPIb binding site [78], indicating that flavocetin-A is bifunctional.
Although the 3D structure of GPIb and GPIb-binding protein complex has not been elucidated, the binding site of GPIb on GPIb-binding proteins has been examined. The biological activity of echicetin is present in the β-subunit but not α-subunit, as seen from experiments using reduced and alkylated subunits [70,79]. Two hydrophilic patches in the β-subunit of flavocetin-A are considered to be the GPIb binding site [75]. Agkicetin-C has been found to bind the region between 201 and 282 of GPIbα [65].

5. Perspectives

Snake venoms comprise a natural library of valuable bioactive substances for hemostasis and thrombosis. The snake venom cofactors described here are useful for clinical evaluation or sub-diagnosis of bleeding disorders as well as for basic investigation into the molecular mechanisms of platelet plug formation induced by VWF and platelets. However, it has become quite difficult to obtain crude venom samples from foreign countries after the adoption of the Washington Convention, which controls the international trade of endangered species [80]. Studies of snake venoms at the protein level might be limited to certain countries of Asia, Africa, and the Americas, where a variety of snakes range. Thus, patience is required to protect and maintain natural scarce animals so that recombinant studies at the genetic level might lead to numerous benefits.

Disintegrins have shed light on drug design of anti-platelet plugs and elicited efficient anti-hemostatic effects in several therapeutic trials [81]. More diverse clinical trials should be focused toward a variety of thrombotic diseases. Formulation of the tablet form of disintegrin, which is more stable, may be feasible through coupling to digestive proteins.

For VWF cofactor proteins, evaluation of VWF activity using these proteins should be superior to ristocetin in sensitivity and accuracy. Recombinant cofactor proteins purified to homogeneity are expected to be used as a standard assay reagent instead of ristocetin in the future. A goal is to find a novel VWF-binding protein that blocks the interaction between GPIb and VWF, making it more preferable for controlling platelet plug formation as it blocks the GPIb binding activity of VWF without inducing signal transduction in platelets.

GPIb antagonists inhibit platelet agglutination in vitro; however, echicetin or agkicetin induce thrombocytopenia when injected in rats, indicating that unknown interactions leading to platelet aggregation are invoked in vivo by administration of these antagonists. In physiological circulating blood, shear-stress might also give rise to an effective signal on platelets complexed with GPIb-binding proteins. Further, immunological response would exclude snake venom-derived materials when it was administered long-term, since there was no similar protein in human to the C-type lectin-like snake venom proteins. These results suggest that GPIb-antagonists are not clinically applicable at present, but if the key domain for eliciting GPIb binding could be straitened like a peptide aptamer [82], anti-platelet plug drugs could result. Furthermore, both GPIb-antagonists and agonists are potential reagents for investigating the platelet activation pathway originating from GPIb [83,84].

The snake is a symbol of medical knowledge from ancient times. Fittingly, the continuing study of snake venom components is bringing to light useful knowledge of thrombosis and hemostasis.
References

1. Sadler, J.E. von Willebrand factor: Two sides of a coin. *J. Thromb. Haemost.* **2005**, *3*, 1702–1709.
2. Ruggeri, Z.M. The role of von Willebrand factor in thrombus formation. *Thromb. Res.* **2007**, *120* (Suppl 1), S5–S9.
3. Ouyang, C.; Teng, C.M.; Huang, T.F. Characterization of snake venom components acting on blood coagulation and platelet function. *Toxicon* **1992**, *30*, 945–966.
4. Matsui, T.; Fujimura, Y.; Titani, K. Snake venom proteases affecting hemostasis and thrombosis. *Biochim. Biophys. Acta* **2000**, *1477*, 146–156.
5. Matsui, T.; Hamako, J. Structure and function of snake venom toxins interacting with human von Willebrand factor. *Toxicon* **2005**, *45*, 1075–1087.
6. Andrews, R.K.; Gardiner, E.E.; Berndt, M.C. Snake venom toxins affecting platelet function. *Methods Mol. Biol.* **2004**, *273*, 335–348.
7. Marsh, N.A. Diagnostic uses of snake venom. *Haemostasis* **2001**, *31*, 211–217.
8. Marsh, N.; Williams, V. Practical applications of snake venom toxins in haemostasis. *Toxicon* **2005**, *45*, 1171–1181.
9. Clemetson, K.J.; Clemetson, J.M. Platelet GPIb complex as a target for anti-thrombotic drug development. *Thromb. Haemost.* **2008**, *99*, 473–479.
10. Huang, T.F.; Holt, J.C.; Lukasiewicz, H.; Niewiarowski, S. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. *J. Biol. Chem.* **1987**, *262*, 16157–16163.
11. Huang, T.F.; Holt, J.C.; Kirby, E.P.; Niewiarowski, S. Trigramin: Primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. *Biochemistry* **1989**, *28*, 661–666.
12. McLane, M.A.; Paquette-Straub, C. Scientific and standardization committee communications: Classification and nomenclature of disintegrins isolated from snake venoms. *J. Thromb. Haemost.* **2007**, *5*, 1971.
13. McLane, M.A.; Sanchez, E.E.; Wong, A.; Paquette-Straub, C.; Perez, J.C. Disintegrins. *Curr. Drug Targets Cardiovasc. Haematol. Disord.* **2004**, *4*, 327–355.
14. Moiseeva, N.; Bau, R.; Swenson, S.D.; Markland, F.S., Jr.; Choe, J.Y.; Liu, Z.J.; Allaire, M. Structure of acostatin, a dimeric disintegrin from Southern copperhead (*Agkistrodon contortrix contortrix*), at 1.7 A resolution. *Acta Crystallogr. D. Biol. Crystallogr.* **2008**, *64*, 466–470.
15. Adler, M.; Lazarus, R.A.; Dennis, M.S.; Wagner, G. Solution structure of kistrin, a potent platelet aggregation inhibitor and GP Ib-IIIa antagonist. *Science* **1991**, *253*, 445–448.
16. Monleon, D.; Esteve, V.; Kovacs, H.; Calvete, J.J.; Celda, B. Conformation and concerted dynamics of the integrin-binding site and the C-terminal region of echistatin revealed by homonuclear NMR. *Biochem. J.* **2005**, *387*, 57–66.
17. Fujii, Y.; Okuda, D.; Fujimoto, Z.; Horii, K.; Morita, T.; Mizuno, H. Crystal structure of trimestatin, a disintegrin containing a cell adhesion recognition motif RGD. *J. Mol. Biol.* **2003**, *332*, 1115–1122.
18. Shin, J.; Hong, S.Y.; Chung, K.; Kang, I.; Jang, Y.; Kim, D.S.; Lee, W. Solution structure of a novel disintegrin, salmosin, from *Agkistrond halys* venom. *Biochemistry 2003*, *42*, 14408–14415.

19. Bilgrami, S.; Tomar, S.; Yadav, S.; Kaur, P.; Kumar, J.; Jabeen, T.; Sharma, S.; Singh, T.P. Crystal structure of schistatin, a disintegrin homodimer from saw-scaled viper (*Echis carinatus*) at 2.5 A resolution. *J. Mol. Biol. 2004*, *341*, 829–837.

20. Bilgrami, S.; Yadav, S.; Kaur, P.; Sharma, S.; Perbandt, M.; Betzel, C.; Singh, T.P. Crystal structure of the disintegrin heterodimer from saw-scaled viper (*Echis carinatus*) at 1.9 A resolution. *Biochemistry 2005*, *44*, 11058–11066.

21. Sayle, R.A.; Milner-White, E.J. RASMOL: Biomolecular graphics for all. *Trends. Biochem. Sci. 1995*, *20*, 374.

22. Kim, J.; Hong, S.Y.; Park, H.S.; Kim, D.S.; Lee, W. Structure and function of RGD peptides derived from disintegrin proteins. *Mol. Cells 2005*, *19*, 205–211.

23. Scarborough, R.M.; Rose, J.W.; Hsu, M.A.; Phillips, D.R.; Fried, V.A.; Campbell, A.M.; Nannizzi, L.; Charo, I.F. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of *Sistrurus m. barbouri*. *J. Biol. Chem. 1991*, *266*, 9359–9362.

24. Scarborough, R.M.; Naughton, M.A.; Teng, W.; Rose, J.W.; Phillips, D.R.; Nannizzi, L.; Arfsten, A.; Campbell, A.M.; Charo, I.F. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. *J. Biol. Chem. 1993*, *268*, 1066–1073.

25. Scarborough, R.M. Development of eptifibatide. *Am. Heart. J. 1999*, *138*, 1093–1104.

26. Phillips, D.R.; Scarborough, R.M. Clinical pharmacology of eptifibatide. *Am. J. Cardiol. 1997*, *80*, 11B-20B.

27. Plosker, G.L.; Ibbotson, T. Eptifibatide: A pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. *Pharmacoeconomics 2003*, *21*, 885–912.

28. Zeymer, U.; Wienbergen, H. A review of clinical trials with eptifibatide in cardiology. *Cardiovasc. Drug Rev. 2007*, *25*, 301–315.

29. Sheffield, W.P.; Gataiance, S.; Eltringham-Smith, L.J. Combined administration of barbourin-albumin and hirudin-albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta. *Thromb. Res. 2007*, *119*, 195–207.

30. Lu, X.; Lu, D.; Scully, M.F.; Kakkar, V.V. Snake venom metalloproteinase containing a disintegrin-like domain, its structure-activity relationships at interacting with integrins. *Curr. Med. Chem. Cardiovasc. Hematol. Agents 2005*, *3*, 249–260.

31. McLane, M.A.; Marcinkiewicz, C.; Vijay-Kumar, S.; Wierzbicka-Patynowski, I.; Niewiarowski, S. Viper venom disintegrins and related molecules. *Proc. Soc. Exp. Biol. Med. 1998*, *219*, 109–119.

32. Myles, D.G.; Kimmel, L.H.; Blobel, C.P.; White, J.M.; Primakoff, P. Identification of a binding site in the disintegrin domain of fertilin required for sperm-egg fusion. *Proc. Natl. Acad. Sci. USA 1994*, *91*, 4195–4198.

33. Yagami-Hiromasa, T.; Sato, T.; Kurisaki, T.; Kamijo, K.; Nabeshima, Y.; Fujisawa-Sehara, A. A metalloprotease-disintegrin participating in myoblast fusion. *Nature 1995*, *377*, 652–656.

34. Blobel, C.P. Metalloprotease-disintegrins: Links to cell adhesion and cleavage of TNF alpha and Notch. *Cell 1997*, *90*, 589–592.
35. Ito, M.; Hamako, J.; Sakurai, Y.; Matsumoto, M.; Fujimura, Y.; Suzuki, M.; Hashimoto, K.; Titani, K.; Matsui, T. Complete amino acid sequence of kaouthiagin, a novel cobra venom metalloproteinase with two disintegrin-like sequences. Biochemistry 2001, 40, 4503–4511.

36. Hamako, J.; Matsui, T.; Nishida, S.; Nomura, S.; Fujimura, Y.; Ito, M.; Ozeki, Y.; Titani, K. Purification and characterization of kaouthiagin, a von Willebrand factor-binding and -cleaving metalloproteinase from Naha kaouthia cobra venom. Thromb. Haemost. 1998, 80, 499–505.

37. Brinkhous, K.M.; Fricke, W.A.; Read, M.S. Determinants of von Willebrand factor activity elicited by ristocetin and botrocetin: Studies on a human von Willebrand factor-binding antibody. Semin. Thromb. Hemost. 1985, 11, 337–341.

38. Scott, J.P.; Montgomery, R.R.; Retzinger, G.S. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J. Biol. Chem. 1991, 266, 8149–8155.

39. Read, M.S.; Shermer, R.W.; Brinkhous, K.M. Venom coagglutinin: An activator of platelet aggregation dependent on von Willebrand factor. Proc. Natl. Acad. Sci. USA 1978, 75, 4514–4518.

40. Read, M.S.; Smith, S.V.; Lamb, M.A.; Brinkhous, K.M. Role of botrocetin in platelet agglutination: Formation of an activated complex of botrocetin and von Willebrand factor. Blood 1989, 74, 1031–1035.

41. Usami, Y.; Fujimura, Y.; Suzuki, M.; Ozeki, Y.; Nishio, K.; Fukui, H.; Titani, K. Primary structure of two-chain botrocetin, a von Willebrand factor modulator purified from the venom of Bothrops jararaca. Proc. Natl. Acad. Sci. USA 1993, 90, 928–932.

42. Matsui, T.; Hamako, J.; Suzuki, M.; Hayashi, N.; Ito, M.; Makita, K.; Fujimura, Y.; Ozeki, Y.; Titani, K. Complete amino acid sequence of bitiscetin, a novel von Willebrand factor modulator protein, purified from snake venom of Bitis arietans. Res. Commun. Biochem. Cell Mol. Biol. 1997, 1, 271–284.

43. Kawasaki, T.; Fujimura, Y.; Usami, Y.; Suzuki, M.; Miura, S.; Sakurai, Y.; Makita, K.; Taniuchi, Y.; Hirano, K.; Titani, K. Complete amino acid sequence and identification of the platelet glycoprotein Ib-binding site of jararaca GPIb-BP, a snake venom protein isolated from Bothrops jararaca. J. Biol. Chem. 1996, 271, 10635–10639.

44. Fukuda, K.; Doggett, T.; Laurenzi, I.J.; Liddington, R.C.; Diacovo, T.G. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat. Struct. Mol. Biol. 2005, 12, 152–159.

45. Sen, U.; Vasudevan, S.; Subbarao, G.; McClintock, R.A.; Celikel, R.; Ruggeri, Z.M.; Varughese, K.I. Crystal structure of the von Willebrand factor modulator botrocetin. Biochemistry 2001, 40, 345–352.

46. Hirotsu, S.; Mizuno, H.; Fukuda, K.; Qi, M.C.; Matsui, T.; Hamako, J.; Morita, T.; Titani, K. Crystal structure of bitiscetin, a von Willebrand factor-dependent platelet aggregation inducer. Biochemistry 2001, 40, 13592–13597.

47. Matsushita, T.; Meyer, D.; Sadler, J.E. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J. Biol. Chem. 2000, 275, 11044–11049.
48. Maita, N.; Nishio, K.; Nishimoto, E.; Matsui, T.; Shikamoto, Y.; Morita, T.; Sadler, J.E.; Mizuno, H. Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: Insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins. *J. Biol. Chem.* 2003, 278, 37777–37781.

49. Matsui, T.; Hamako, J.; Matsushita, T.; Nakayama, T.; Fujimura, Y.; Titani, K. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer. *Biochemistry* 2002, 41, 7939–7946.

50. Obert, B.; Romijn, R.A.; Houllier, A.; Huizinga, E.G.; Girma, J.P. Characterization of bitiscetin-2, a second form of bitiscetin from the venom of *Bitis arietans* : Comparison of its binding site with the collagen-binding site on the von Willebrand factor A3-domain. *J. Thromb. Haemost.* 2006, 4, 1596–1601.

51. Mizuno, H.; Fujimoto, Z.; Koizumi, M.; Kano, H.; Atoda, H.; Morita, T. Structure of coagulation factors IX/X-binding protein, a heterodimer of C-type lectin domains. *Nat. Struct. Biol.* 1997, 4, 438–441.

52. Atoda, H.; Ishikawa, M.; Mizuno, H.; Morita, T. Coagulation factor X-binding protein from *Deinagkistrodon acutus* venom is a Gla domain-binding protein. *Biochemistry* 1998, 37, 17361–17370.

53. Fukuda, K.; Mizuno, H.; Atoda, H.; Morita, T. Crystallization and preliminary x-ray studies of flavocetin-A, a platelet glycoprotein Ib-binding protein from the habu snake venom. *Acta Crystallogr. D. Biol. Crystallogr.* 1999, 55, 1911–1913.

54. Murakami, M.T.; Zela, S.P.; Gava, L.M.; Michelan-Duarte, S.; Cintra, A.C.; Arni, R.K. Crystal structure of the platelet activator convulxin, a disulfide-linked alpha4beta4 cyclic tetramer from the venom of *Crotalus durissus terrificus*. *Biochem. Biophys. Res. Commun.* 2003, 310, 478–482.

55. Moreland, J.L.; Gramada, A.; Buzko, O.V.; Zhang, Q.; Bourne, P.E. The Molecular Biology Toolkit (MBT): A modular platform for developing molecular visualization applications. *BMC Bioinf.* 2005, 6, 21.

56. Miura, S.; Li, C.Q.; Cao, Z.; Wang, H.; Wardell, M.R.; Sadler, J.E. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. *J. Biol. Chem.* 2000, 275, 7539–7546.

57. Fukuda, K.; Doggett, T.A.; Bankston, L.A.; Cruz, M.A.; Diacovo, T.G.; Liddington, R.C. Structural basis of von Willebrand factor activation by the snake toxin botrocetin. *Structure* 2002, 10, 943–950.

58. Marchese, P.; Murata, M.; Mazzucato, M.; Pradella, P.; De Marco, L.; Ware, J.; Ruggeri, Z.M. Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alpha-thrombin binding. *J. Biol. Chem.* 1995, 270, 9571–9578.

59. Dong, J.; Ye, P.; Schade, A.J.; Gao, S.; Romo, G.M.; Turner, N.T.; McIntire, L.V.; Lopez, J.A. Tyrosine sulfation of glycoprotein I(b)alpha. Role of electrostatic interactions in von Willebrand factor binding. *J. Biol. Chem.* 2001, 276, 16690–16694.

60. Peng, M.; Lu, W.; Kirby, E.P. Alboaggregin-B: A new platelet agonist that binds to platelet membrane glycoprotein Ib. *Biochemistry* 1991, 30, 11529–11536.

61. Peng, M.; Lu, W.; Kirby, E.P. Characterization of three alboaggregins purified from *Trimeresurus albolabris* venom. *Thromb. Haemost.* 1992, 67, 702–707.
62. Sakurai, Y.; Fujimura, Y.; Kokubo, T.; Imamura, K.; Kawasaki, T.; Handa, M.; Suzuki, M.; Matsui, T.; Titani, K.; Yoshioka, A. The cDNA cloning and molecular characterization of a snake venom platelet glycoprotein Ib-binding protein, mamushigin, from Agkistrodon halys blomhoffii venom. *Thromb. Haemost.* 1998, 79, 1199–1207.

63. Du, X.Y.; Navdaev, A.; Clemetson, J.M.; Magnenat, E.; Wells, T.N.; Clemetson, K.J. Bilinexin, a snake C-type lectin from Agkistrodon bilineatus venom agglutinates platelets via GPIb and alpha2beta1. *Thromb. Haemost.* 2001, 86, 1277–1283.

64. Wang, W.J.; Huang, T.F. A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist. *Thromb. Haemost.* 2001, 86, 1077–1086.

65. Xu, G.; Ulrichs, H.; Vauterin, S.; De Meyer, S.F.; Deckmyn, H.; Teng, M.; Niu, L. How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects? *Toxicon* 2005, 45, 561–570.

66. Lu, Q.; Navdaev, A.; Clemetson, J.M.; Clemetson, K.J. GPIb is involved in platelet aggregation induced by mucetin, a snake C-type lectin protein from Chinese habu (Trimeresurus mucrosquamatus) venom. *Thromb. Haemost.* 2004, 91, 1168–1176.

67. Huang, K.F.; Ko, T.P.; Hung, C.C.; Chu, J.; Wang, A.H.; Chiou, S.H. Crystal structure of a platelet-agglutinating factor isolated from the venom of Taiwan habu (Trimeresurus mucrosquamatus). *Biochem. J.* 2004, 378, 399–407.

68. Wang, W.J.; Ling, Q.D.; Liau, M.Y.; Huang, T.F. A tetrameric glycoprotein Ib-binding protein, agglucetin, from Formosan pit viper: Structure and interaction with human platelets. *Thromb. Haemost.* 2003, 90, 465–475.

69. Lu, Q.; Clemetson, J.M.; Clemetson, K.J. Translocation of GPIb and Fc receptor gamma-chain to cytoskeleton in mucetin-activated platelets. *J. Thromb. Haemost.* 2005, 3, 2065–2076.

70. Peng, M.; Lu, W.; Beviglia, L.; Niewiarowski, S.; Kirby, E.P. Echicetin: A snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib. *Blood* 1993, 81, 2321–2328.

71. Taniuchi, Y.; Kawasaki, T.; Fujimura, Y.; Suzuki, M.; Titani, K.; Sakai, Y.; Kaku, S.; Hisamichi, N.; Satoh, N.; Takenaka, T.; Flavocetin-A and -B, two high molecular mass glycoprotein Ib binding proteins with high affinity purified from Trimeresurus flavoviridis venom, inhibit platelet aggregation at high shear stress. *Biochim. Biophys. Acta* 1995, 1244, 331–338.

72. Kawasaki, T.; Taniuchi, Y.; Hisamichi, N.; Fujimura, Y.; Suzuki, M.; Titani, K.; Sakai, Y.; Kaku, S.; Satoh, N.; Takenaka, T.; Tokaracetin, a new platelet antagonist that binds to platelet glycoprotein ib and inhibits von Willebrand factor-dependent shear-induced platelet aggregation. *Biochem. J.* 1995, 308 (Pt 3), 947–953.

73. Fujimura, Y.; Ikeda, Y.; Miura, S.; Yoshida, E.; Shima, H.; Nishida, S.; Suzuki, M.; Titani, K.; Taniuchi, Y.; Kawasaki, T. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib. *Thromb. Haemost.* 1995, 74, 743–750.

74. Zhong, S.R.; Jin, Y.; Wu, J.B.; Chen, R.Q.; Jia, Y.H.; Wang, W.Y.; Xiong, Y.L.; Zhang, Y. Characterization and molecular cloning of dabocetin, a potent antplatelet C-type lectin-like protein from Daboia russellii siamensis venom. *Toxicon* 2006, 47, 104–112.
75. Fukuda, K.; Mizuno, H.; Atoda, H.; Morita, T. Crystal structure of flavocetin-A, a platelet glycoprotein Ib-binding protein, reveals a novel cyclic tetramer of C-type lectin-like heterodimers. *Biochemistry* **2000**, *39*, 1915–1923.

76. Jasti, J.; Paramasivam, M.; Srinivasan, A.; Singh, T.P. Crystal structure of echicetin from *Echis carinatus* (Indian saw-scaled viper) at 2.4Å resolution. *J. Mol. Biol.* **2004**, *335*, 167–176.

77. Xu, G.; Huang, Q.; Teng, M.; Liu, P.; Dong, Y.; Niu, L. Crystallization and preliminary X-ray crystallographic analysis of agkicetin-C from *Deinagkistrodon acutus* venom. *Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun.* **2005**, *61*, 75–78.

78. Taniuchi, Y.; Kawasaki, T.; Fujimura, Y. The high molecular mass, glycoprotein Ib-binding protein flavocetin-A induces only small platelet aggregates *in vitro*. *Thromb. Res.* **2000**, *97*, 69–75.

79. Peng, M.; Holt, J.C.; Niewiarowski, S. Isolation, characterization and amino acid sequence of echicetin beta subunit, a specific inhibitor of von Willebrand factor and thrombin interaction with glycoprotein Ib. *Biochem. Biophys. Res. Commun.* **1994**, *205*, 68–72.

80. Williams, W. Endangered species. CITES puts off plan to hasten shipments. *Science* **2000**, *288*, 592.

81. Zeymer, U. The role of eptifibatide in patients undergoing percutaneous coronary intervention. *Expert Opin. Pharmacother.* **2007**, *8*, 1147–1154.

82. Hoppe-Seyler, F.; Crnkovic-Meretens, I.; Tomai, E.; Butz, K. Peptide aptamers: Specific inhibitors of protein function. *Curr. Mol. Med.* **2004**, *4*, 529–538.

83. Liu, J.; Joglekar, M.; Ware, J.; Fitzgerald, M.E.; Lowell, C.A.; Berndt, M.C.; Gartner, T.K. Evaluation of the physiological significance of botrocetin/von Willebrand factor *in vitro* signaling. *J. Thromb. Haemost.* **2008**, *6*, 1915–1922.

84. Liu, J.; Fitzgerald, M.E.; Berndt, M.C.; Jackson, C.W.; Gartner, T.K. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation *in vivo*. *Blood* **2006**, *108*, 2596–2603.

© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).